Some weight loss drugs may increase risk of gastrointestinal diseases: Canadian study | World News - Hindustan Times
close_game
close_game

Some weight loss drugs may increase risk of gastrointestinal diseases: Canadian study

Oct 06, 2023 05:15 PM IST

GLP-1 agonists were originally developed for targeting Type 2 diabetes but have become increasingly used for weight loss regimens

Some popular weight loss drugs may increase the risk of gastrointestinal diseases, according to a new Canadian study.

Some popular brands of medications are found to be associated with an increased risk of serious medical conditions including stomach paralysis, pancreatitis and bowel obstruction. (Source: University of British Columbia)
Some popular brands of medications are found to be associated with an increased risk of serious medical conditions including stomach paralysis, pancreatitis and bowel obstruction. (Source: University of British Columbia)

New research from the University of British Columbia (UBC) found that popular brands of medications known as GLP-1 agonists, including Wegovy, Ozempic, Rybelsus and Saxenda, “are associated with an increased risk of serious medical conditions including stomach paralysis, pancreatitis and bowel obstruction”, a release from UBC said.

Hindustan Times - your fastest source for breaking news! Read now.

While these risks were underscored in earlier studies for patients with diabetes, UBC said this was the first “large, population-level study to examine adverse gastrointestinal events in non-diabetic patients using the drugs specifically for weight loss”.

The findings were published in the journal JAMA.

The first author of the study was Indo-Canadian Mohit Sodhi, who said, “Given the wide use of these drugs, these adverse events, although rare, must be considered by patients thinking about using them for weight loss.”

Sodhi, a graduate of UBC’s experimental medicine programme and fourth year UBC medical student, added, “The risk calculus will differ depending on whether a patient is using these drugs for diabetes, obesity or just general weight loss. People who are otherwise healthy may be less willing to accept these potentially serious adverse events.”

GLP-1 agonists were originally developed for targeting Type 2 diabetes but have become increasingly used for weight loss regimens.

The researchers compared the effects of these drugs to bupropion-naltrexone, also used for weight loss. They found that there was 9.09 times higher risk of pancreatitis or inflammation of the pancreas, the risk for bowel obstruction was at 4.22 and for gastroparesis or stomach paralysis was at 3.67 times.

Sodhi said, “These drugs are becoming increasingly accessible, and it is concerning that, in some cases, people can simply go online and order these kind of medications when they may not have a full understanding of what could potentially happen. This goes directly against the mantra of informed consent.”

Unlock a world of Benefits with HT! From insightful newsletters to real-time news alerts and a personalized news feed – it's all here, just a click away! - Login Now! Get Latest World News along with Latest News from India at Hindustan Times.
SHARE THIS ARTICLE ON
Share this article
  • ABOUT THE AUTHOR
    author-default-90x90

    Anirudh Bhattacharya is a Toronto-based commentator on North American issues, and an author. He has also worked as a journalist in New Delhi and New York spanning print, television and digital media. He tweets as @anirudhb.

SHARE
Story Saved
Live Score
Saved Articles
Following
My Reads
Sign out
New Delhi 0C
Thursday, February 22, 2024
Start 14 Days Free Trial Subscribe Now
Follow Us On